Payers Have Biologic Alternative for Patients With Moderate to Severe Rheumatoid Arthritis Who Do Not Respond to Other DMARD Therapies.
作者信息
Bell Sally
出版信息
Biotechnol Healthc. 2006 Dec;3(6):24-8.
Abstract
Earlier biologic therapies for rheumatoid arthritis represented a breakthrough in treatment of the disease, but there are still some patients who do not respond adequately to them. The market entry of abatacept, which allows for consistent dosing and predictable drug-acquisition costs, presents patients, physicians, and third-party payers with an effective alternative - the first therapy proven to be effective in patients with inadequate response to DMARDs such as methotrexate or anti-TNF-alpha therapies.
摘要
相似文献
1
Payers Have Biologic Alternative for Patients With Moderate to Severe Rheumatoid Arthritis Who Do Not Respond to Other DMARD Therapies.
Biotechnol Healthc. 2006 Dec;3(6):24-8.
2
Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.
Clin Rheumatol. 2009 Apr;28(4):403-12. doi: 10.1007/s10067-008-1060-4. Epub 2008 Dec 17.
3
Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Am J Med. 2015 May;128(5):539.e7-17. doi: 10.1016/j.amjmed.2014.11.025. Epub 2014 Dec 20.
4
Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis.
Clin Rheumatol. 2010 Jun;29(6):583-91. doi: 10.1007/s10067-009-1363-0. Epub 2010 Jan 23.
5
Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
Mod Rheumatol. 2015 May;25(3):350-7. doi: 10.3109/14397595.2014.958274. Epub 2015 Jan 25.
6
Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept.
Clin Drug Investig. 2009;29(3):185-202. doi: 10.2165/00044011-200929030-00005.
7
The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
Best Pract Res Clin Rheumatol. 2012 Oct;26(5):659-76. doi: 10.1016/j.berh.2012.07.012.
8
Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
BioDrugs. 2012 Apr 1;26(2):65-70. doi: 10.2165/11631320-000000000-00000.
9
Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Rheumatol Int. 2017 Sep;37(9):1469-1479. doi: 10.1007/s00296-017-3749-7. Epub 2017 Jun 9.
10
Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
Clin Exp Rheumatol. 2011 Jul-Aug;29(4):633-41. Epub 2011 Aug 31.
本文引用的文献
1
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.
Ann Intern Med. 2006 Jun 20;144(12):865-76. doi: 10.7326/0003-4819-144-12-200606200-00003.
2
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
N Engl J Med. 2005 Sep 15;353(11):1114-23. doi: 10.1056/NEJMoa050524.
3
Rheumatoid arthritis: an overview of new and emerging therapies.
J Clin Pharmacol. 2005 Jul;45(7):751-62. doi: 10.1177/0091270005277938.
4
T-cell regulation in rheumatoid arthritis.
Curr Opin Rheumatol. 2004 May;16(3):212-7. doi: 10.1097/00002281-200405000-00008.
5
Therapeutic strategies for rheumatoid arthritis.
Nat Rev Drug Discov. 2003 Jun;2(6):473-88. doi: 10.1038/nrd1109.
6
Guidelines for the management of rheumatoid arthritis: 2002 Update.
Arthritis Rheum. 2002 Feb;46(2):328-46. doi: 10.1002/art.10148.
7
Induction, binding specificity and function of human ICOS.
Eur J Immunol. 2000 Dec;30(12):3707-17. doi: 10.1002/1521-4141(200012)30:12<3707::AID-IMMU3707>3.0.CO;2-Q.
8
Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection.
J Immunol. 1999 Jun 1;162(11):6708-15.
9
Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States.
Arthritis Rheum. 1998 May;41(5):778-99. doi: 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V.
Zotero 插件